Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Merck & Co’s chief executive shares views on the need for “reasonable” returns on COVID-19 therapeutics and vaccines, and on the future US pricing environment, at the USAIC summit.

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.